Novartis stepping up vaccine call to pre-empt pandemic
Novartis, the Swiss pharmaceutical group, is stepping up the case for use of its experimental pandemic flu vaccine even ahead of a new virus mutation that could trigger a future lethal outbreak in humans. Jorg Reinhardt, head of vaccines and diagnostics, said the company would publish scientific data showing that its H5 vaccine stimulates rapid protection with a second booster jab against pandemic flu strains for at least seven years. Many specialists believe two flu injections may be necessary to provide significant protection from a pandemic, but there is far less current global capacity than supply. Reinhardt said a single flu vaccine shot would normally only offer protection after four to six weeks, but an initial jab would allow a subsequent booster to become effective within two to three days. His remarks come at a time of fierce competition between vaccine companies, which have invested significantly in pandemic flu and are attempting to recover their costs as international concern wanes. Companies including Baxter, Sanofi-Aventis and Solvay are all making arguments for the advantages of their own products, and GlaxoSmithKline raised the profile of its H5N1 vaccine last year when it agreed to donate to a "solidarity' stockpile for poor countries. World Health Organisation officials caution against labelling such products "pre-pandemic' vaccines, because they will only be effective if it is a mutation of the current H5N1 bird flu strain that triggers a pandemic. Others remain cautious about any preventative vaccination because of the cost and strain on public health systems, and concern that widespread use could trigger side effects. Reinhardt stressed it was up to the governments to decide whether or not to buy and use his vaccine. "We will share the data with everyone who is willing to listen and make the scientific argument that it provides protection,' he said. His comments came as Novartis unveiled a new Institute for Global Health at its vaccines research office in Siena, which will attempt to develop non-profit vaccines to protect against three salmonella-based infections that cause diarrhoea, one of the leading causes of disease and death in young children around the world. He said the institute, mirroring its work in Singapore to find medicines to treat illnesses for which there is no commercial market, would employ 50 scientists within three years and seek support from funds such as the Bill & Melinda Gates Foundation and the Wellcome Institute by the end of this year.